Navigation Links
Aldea Pharmaceuticals Closes $24 Million Series B Financing
Date:8/24/2014

REDWOOD CITY, Calif., Aug. 25, 2014 /PRNewswire/ -- Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing. The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners and Correlation Ventures also participated in the round.

The financing will be used to advance Aldea's lead drug candidate, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room (ER) setting. In addition, Aldea is studying oral AD-6626 for the treatment of subjects with the rare genetic disease Fanconi anemia, and anticipates the financing will support a Phase 1/2 proof-of-biology study in that indication.

Every year, millions of Americans are admitted to the ER as a result of clinically significant acute alcohol intoxication, and an estimated 10 to 15 percent of ER visits are associated with alcohol consumption. Acute alcohol toxicity can be life-threatening and can lead to ER crowding, delays in critical treatment for trauma patients and intensive use of hospital resources. Since there is no antidote treatment available for alcohol toxicity, patients with acute alcohol intoxication must wait for the alcohol to be metabolized from their systems before they can be discharged from the ER.

"The use of AD-6626 in the ER setting has the potential to stabilize patients suffering from acute alcohol toxicity and more rapidly improve the signs and symptoms of intoxication than waiting for alcohol metabolism, thereby simplifying patient care. This could facilitate treatment in individuals suffering from co-morbidities such as trauma, as well as benefiting the system as a whole," noted William Yelle, chief executive officer of Aldea. "We also have the opportunity to apply our scientific approach in the treatment of patients with Fanconi anemia, a rare genetic disease characterized by chromosomal instability, bone marrow failure and an increased risk of cancer. The funds we have secured with this financing should allow us to generate proof-of-concept data in both of these indications."

About Aldea Pharmaceuticals
Aldea Pharmaceuticals is focused on developing small molecule modulators of the aldehyde dehydrogenase enzyme superfamily. The scientific approach was discovered by Stanford University researchers and exclusively licensed to Aldea. Aldea is pursuing treatment of clinically significant acute alcohol toxicity, Fanconi anemia and other diseases and conditions associated with toxic aldehydes.


'/>"/>
SOURCE Aldea Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):